Blog Archives

Theragenomic medicine: Accurate treatment response prediction in depressed patients

November 05, 2017 – For some patients knowingly or not knowingly suffering from depression, the upcoming period of the year (i.e., the winter season in the Northern Hemisphere) with grey days and over-porportionally long nights, might be a difficult one. Should such patients enter a antidepressant treatment,

Read more ›

Tags: , , , , , ,

Biomarker-guided Larotrectinib for all cancer types?

June 09, 2017 –  It’s only a couple of days that the American Food & Drug Administration (FDA) approved for the first time a cancer treatment for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

Read more ›

Tags: , , , , , , , , , ,

First cancer treatment for any solid tumor with MSI-H or dMMR approved

May 24, 2917 – The American Food & Drug Administration (FDA) just approved a major extension of the clinical indications for Pembrolizumab (Keytruda). For the first time,  a cancer treatment has been approved for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

Read more ›

Tags: , , , , , , , , ,

Just Wait A Little Longer: Suicide Biomarkers Getting Closer to the Clinic

May 01, 2014 – This is a fantastic article on a very difficult to understand topic, with often very sad outcomes.  The source of the article is Medscape and it reveals how combined efforts from different scientific appoaches may lead to molecular understanding of suicidal behavior,

Read more ›

Tags: , , ,

EMA: Public consultation open on concept paper on pharmacogenomics in evaluation of authorised medicines

January 26, 2012 – I am relaying the information below by the EMA to the readers of this blog. It might be interessting to dwell into this concept paper (as a scientist, a treating physician, or an informed patient) for informations only or even for commenting.

__________________

 The European Medicines Agency (EMA) has released a concept paper on the development of a guideline on the evaluation of pharmacogenomic methodologies in the evaluation of authorised medicines for public consultation.

Read more ›

Tags: , , , , ,

thasso: community

thasso: conditions

thasso post: magazine

View my Flipboard Magazine.

thasso: follow us

thasso: chat

You must be a registered user to participate in this chat.

thasso: tweets

thasso: categories

thasso: archives

Top